Dublin, Jan. 07, 2021 (GLOBE NEWSWIRE) -- The "Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery,Functional Genomics), Indication (Cardiology, Oncology,Inborn Errors), End User (Academic Institute, CROs) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global metabolomics market size is projected to reach USD 4.1 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 13.4% during the forecast period.
The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine, and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry. However, issues related to data examination & data processing in metabolomics and the high cost of tools and instruments are likely to restrain the market growth to a certain extent.
By Product & Service, the metabolomics instrument accounted for the largest share of the metabolomics market.
The metabolomics instrument segment is expected to account for the largest market share in 2020. Factors such as the technological advancements in analytical instruments in terms of miniaturization, automation, and computerization; increase in the number of research-related activities worldwide in the field of medicine, nutraceuticals, and metabolomics; and strengthening healthcare infrastructure in developing nations for efficient disease diagnosis and treatment are expected to propel the growth of this segment during the forecast period
By application, the biomarker discovery segment accounted for the largest share of the metabolomics market.
The biomarker discovery segment is expected to account for the largest market share in 2020. The use of metabolic biomarkers to assess the pathophysiological health status of patients is increasing. In recent years, as a result of significant technological advancements, metabolomics has become a vital tool in discovering biomarkers.
By Indication, the Cancer segment expected to grow at the fastest growth rate during the forecast period.
Based on indication, the metabolomics market has been segmented into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications (respiratory and infectious diseases. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent
increase in the demand for cancer therapies.
By End-user, Academic and Research Institutes accounted for the largest share of the metabolomics market.
The academic and research institutes segment accounted for the largest share of the metabolomics market in 2020. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.
Asia Pacific: The fastest-growing region in the metabolomics market.
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.
North America: The largest share of the metabolomics market.
North America, which includes the US and Canada, accounted for the largest share of the metabolomics market. The large share of the North America region can be attributed to the presence of major players operating in the metabolomics market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Metabolomics Market Overview
4.2 Asia-Pacific: Metabolomics Market Share, by Product and Service and by Country (2019)
4.3 Metabolomics Market Size, by Detection Tools
4.4 Metabolomics Market Share, by Separation Tools, 2020 Vs. 2025
5 Market Overview
5.2 Market Dynamics
5.2.1 Key Market Drivers
184.108.40.206 Availability of Government and Private Funding for Metabolomics Research
220.127.116.11 Increasing Pharmaceutical and Biotech R&D Expenditure
18.104.22.168 Growing Demand for Personalized Medicine
5.2.2 Key Market Restraints
22.214.171.124 Issues Related to Data Examination and Processing
126.96.36.199 High Cost of Tools and Instruments
5.2.3 Key Market Opportunities
188.8.131.52 Biomarker Development
184.108.40.206 Lucrative Opportunities in Emerging Markets
5.2.4 Key Market Challenges
220.127.116.11 Complexity and Diversity of Biological Samples
18.104.22.168 Dearth of Skilled Researchers
5.3 Impact of COVID-19 on Growth of Metabolomics Market
6 Industry Insights
6.2 Industry Trends
6.2.1 Increasing Adoption of Hyphenated Technologies
6.2.2 Tie-Ups Between Instrument Manufacturers and Research Laboratories/Academic Institutions
6.3 Regulatory Analysis
7 Technology Investment Potential
7.2 Investment Client Networks
7.3 Funding Bodies/Initiatives
7.4 Analysis of Potential Areas for Technology Investment Using Strategic Evaluation
7.4.1 Parameters Considered for Emerging Opportunity Evaluation
22.214.171.124 Level of Attractiveness
126.96.36.199 Probability of Success
7.4.2 Opportunity Strategic Evaluation Analysis
7.4.3 Description of Opportunities
188.8.131.52 Viable (Quadrant 1) - Biomarker Discovery and Lead Optimization in Drug Discovery
184.108.40.206.1 Biomarker Discovery
220.127.116.11.2 Lead Optimization in Drug Discovery
18.104.22.168.3 Toxicity Testing
22.214.171.124 Promising (Quadrant 2) - Companion Diagnostics for Personalized Medicine and Nutrigenomics
126.96.36.199.1 Companion Diagnostics for Personalized Medicine
188.8.131.52 Challenges (Quadrant 3) - Environmental Metabolomics
184.108.40.206.1 Environmental Metabolomics
220.127.116.11.2 Functional Genomics
8 Metabolomics Market Size, by Product and Service
8.2 Metabolomics Instruments
8.2.1 Separation Tools
8.2.2 High-Performance Liquid Chromatography
18.104.22.168 Growing Use of Hplc in High-Growth Applications to Drive Market Growth
8.2.3 Gas Chromatography
22.214.171.124 Technological Advancements in Gas Chromatography to Drive Adoption of Gc in Metabolome Study
8.2.4 Ultra-Performance Liquid Chromatography
126.96.36.199 Higher Chromatographic Efficiency and Sensitivity of Uplc Would Drive Market Growth
8.2.5 Capillary Electrophoresis
188.8.131.52 Ce is Used in Pathology/Clinical Laboratories Worldwide due to the Low Cost of Reagents, Enhanced Accuracy, and Ease of Operation
8.2.6 Detection Tools
8.2.7 Mass Spectrometry
184.108.40.206 Increasing Use of Mass Spectrometry in Cancer and Genetic Disease Research is Propelling Its Demand
8.2.8 Nuclear Magnetic Resonance Spectroscopy
8.2.9 Surface-Based Mass Analysis
220.127.116.11 Applicability of Surface-Based Mass Analysis Technology in a Wide Range of Samples Would Drive Its Growth
8.3 Metabolomics Bioinformatics Tools & Services
8.3.1 Bioinformatics Services
18.104.22.168 Bioinformatics Services Offer a Simplified Way to Derive Insights from Metabolomics Research
8.3.2 Bioinformatics Tools & Databases
22.214.171.124 Application of Bioinformatics Tools & Databases in Translational Research to Fuel Market Growth
9 Metabolomics Market Size, by Application
9.2 Biomarker Discovery
9.3 Drug Discovery
9.4 Toxicology Testing
9.6 Personalized Medicine
9.7 Functional Genomics
9.8 Other Applications
10 Metabolomics Market Size, by Indication
10.3 Cardiovascular Disorders
10.4 Neurological Disorders
10.5 Metabolic Disorders
10.6 Inborn Errors of Metabolism
11 Metabolomics Market Size, by End-user
11.2 Academic Research Institutes
11.3 Pharmaceutical and Biotechnology Companies
11.4 Contract Research Organizations (Cros)
12 Global Metabolomics Market Size, by Region
12.2 North America
12.5 Latin America
12.6 Middle East & Africa
13 Competitive Landscape
13.2 Market Share Analysis (2019)
13.3 Key Market Developments
13.3.1 Product Launches
13.3.3 Partnerships, Collaborations, and Agreements
14 Company Evaluation Matrix
14.2 Competitive Leadership Mapping: Major Market Players (2019)
14.2.2 Emerging Leaders
14.3 Company Profiles
14.3.1 Thermo Fisher Scientific Inc.
14.3.2 Agilent Technologies, Inc.
14.3.3 Waters Corporation
14.3.4 Danaher Corporation
14.3.5 Shimadzu Corporation
14.3.6 Bio-Rad Laboratories, Inc.
14.3.7 Bruker Corporation
14.3.8 Perkinelmer, Inc.
14.3.9 Merck KGaA
14.3.10 GE Healthcare
14.3.11 Hitachi High-Technologies Corporation
14.3.12 Human Metabolome Technologies, Inc.
14.3.13 Leco Corporation
14.3.14 Metabolon, Inc.
14.3.15 Dani Instruments
14.3.16 Scion Instruments
14.3.17 Gl Sciences
14.3.18 Sri Instruments
14.3.20 Kore Technology
14.3.21 Jasco, Inc.
15.1 Discussion Guide
15.2 Knowledge Store
15.3 Available Customizations
For more information about this report visit https://www.researchandmarkets.com/r/g152z2
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900